A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Amaurosis fugax (painless, temporary loss of vision) One-sided facial droop One-sided motor weakness Diplopia (double vision) Problems with balance and spatial orientation or dizziness Visual field deficits, such as homonymous hemianopsia or monocular blindness Sensory deficits in one or more limbs and of the face Loss of ability to understand or express speech (aphasia) Difficulty with articulation of speech (dysarthria) Unsteady gait Difficulties with swallowing (dysphagia) Numbness or weakness generally occurs on the opposite side of the body from the affected hemisphere of the brain. A detailed neurologic exam, including a thorough cranial nerve exam, is important to identify these findings and to differentiate them from mimickers of TIA. Symptoms such as unilateral weakness, amaurosis fugax, and double vision have higher odds of representing TIA compared to memory loss, headache, and blurred vision. Below is a table of symptoms at presentation, and what percentage of the time they are seen in TIAs versus conditions that mimic TIA. In general, focal deficits make TIA more likely, but the absence of focal findings do not exclude the diagnosis, and further evaluation may be warranted if clinical suspicion for TIA is high (see "Diagnosis" section below).
Nevertheless, alpha-synuclein aggregates to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. These disorders are known as synucleinopathies. In vitro models of synucleinopathies revealed that aggregation of alpha-synuclein may lead to various cellular disorders including microtubule impairment, synaptic and mitochondrial dysfunctions, oxidative stress as well as dysregulation of Calcium signaling, proteasomal and lysosomal pathway. Alpha-synuclein is the primary structural component of Lewy body fibrils. Occasionally, Lewy bodies contain tau protein; however, alpha-synuclein and tau constitute two distinctive subsets of filaments in the same inclusion bodies. Alpha-synuclein pathology is also found in both sporadic and familial cases with Alzheimer's disease. The alpha-synuclein seed amplification assay (SAA) using cerebrospinal fluid demonstrated high diagnostic performance in distinguishing synucleinopathies with Lewy bodies from control subjects. Additionally, SAA kinetics are associated with cognitive impairment and predict the development of dementia. The aggregation mechanism of alpha-synuclein is uncertain. There is evidence of a structured intermediate rich in beta structure that can be the precursor of aggregation and, ultimately, Lewy bodies. A single molecule study in 2008 suggests alpha-synuclein exists as a mix of unstructured, alpha-helix, and beta-sheet-rich conformers in equilibrium.
=== Serie A: 2021–2024 === Salernitana's first match in its return to the top flight was a 3–2 defeat against Bologna on 22 August 2021. After a poor start to the season, earning only one point from the first six matches, the club picked up its first Serie A victory against Genoa on matchday seven, winning 1–0 courtesy of a goal from Milan Đurić. In October, the Salernitana board fired Castori after a 2–1 loss to Spezia had left the club at the bottom of the table, with four points from their opening eight league games. Stefano Colantuono was named as his replacement, returning for a second spell as head coach having previously led Salernitana from December 2017 to December 2018. On 22 May 2022, Salernitana avoided relegation by finishing with the lowest points tally in Serie A history with just 31 points. Salernitana managed to pull off the great escape by securing 18 points from their last 15 matches. In the 2023/2024 Serie A season, Salernitana finished bottom of the table and were relegated back to Serie B. In the 2024-25 season, Salernitana finished 16th, and were sent to the relegation playoffs, losing to Sampdoria 3-0, relegating to Serie C.
However, sodium and potassium form colourless azide salts involving the linear N−3 anion; due to the large size of the alkali metal cations, they are thermally stable enough to be able to melt before decomposing. All the alkali metals react readily with phosphorus and arsenic to form phosphides and arsenides with the formula M3Pn (where M represents an alkali metal and Pn represents a pnictogen – phosphorus, arsenic, antimony, or bismuth). This is due to the greater size of the P3− and As3− ions, so that less lattice energy needs to be released for the salts to form. These are not the only phosphides and arsenides of the alkali metals: for example, potassium has nine different known phosphides, with formulae K3P, K4P3, K5P4, KP, K4P6, K3P7, K3P11, KP10.3, and KP15. While most metals form arsenides, only the alkali and alkaline earth metals form mostly ionic arsenides. The structure of Na3As is complex with unusually short Na–Na distances of 328–330 pm which are shorter than in sodium metal, and this indicates that even with these electropositive metals the bonding cannot be straightforwardly ionic. Other alkali metal arsenides not conforming to the formula M3As are known, such as LiAs, which has a metallic lustre and electrical conductivity indicating the presence of some metallic bonding. The antimonides are unstable and reactive as the Sb3− ion is a strong reducing agent; reaction of them with acids form the toxic and unstable gas stibine (SbH3).
The high percentage of alcohol in absinthe would result in mortality long before thujone could become a factor. In documented cases of acute thujone poisoning as a result of oral ingestion, the source of thujone was not commercial absinthe, but rather non-absinthe-related sources, such as common essential oils (which may contain as much as 50% thujone). One study published in the Journal of Studies on Alcohol concluded that high doses (0.28 mg/kg) of thujone in alcohol had negative effects on attention performance in a clinical setting. It delayed reaction time, and caused subjects to concentrate their attention on the central field of vision. Low doses (0.028 mg/kg) did not produce an effect noticeably different from the plain alcohol control. While the effects of the high dose samples were statistically significant in a double blind test, the test subjects themselves were unable to reliably identify which samples contained thujone. For the average 65 kg (143 lb) man, the high dose samples in the study would equate to 18.2 mg of thujone. The EU limit of 35 mg/L of thujone in absinthe means that given the highest permitted thujone content, that individual would need to consume approximately 0.5 litres of high-proof (e.g. 50%+ ABV) spirit before the thujone could be metabolized to display effects detectable in a clinical setting, which would result in a potentially lethal BAC of >0.4%.
Sources: en.wikipedia.org
=== Inhibin === Quantification of inhibin A is part of the prenatal quad screen that can be administered during pregnancy at a gestational age of 16–18 weeks. An elevated inhibin A (along with an increased beta-hCG, decreased AFP, and a decreased estriol) is suggestive of the presence of a fetus with Down syndrome. As a screening test, abnormal quad screen test results need to be followed up with more definitive tests. It also has been used as a marker for ovarian cancer. Inhibin B may be used as a marker of spermatogenesis function and male infertility. The mean serum inhibin B level is significantly higher among fertile men (approximately 140 pg/mL) than in infertile men (approximately 80 pg/mL). In men with azoospermia, a positive test for inhibin B slightly raises the chances for successfully achieving pregnancy through testicular sperm extraction (TESE), although the association is not very substantial, having a sensitivity of 0.65 (95% confidence interval [CI]: 0.56–0.74) and a specificity of 0.83 (CI: 0.64–0.93) for prediction the presence of sperm in the testes in non-obstructive azoospermia.
=== Topical antifungal === Topically administered ketoconazole is usually prescribed for fungal infections of the skin and mucous membranes, such as athlete's foot, ringworm, candidiasis (yeast infection or thrush), jock itch, and tinea versicolor. Topical ketoconazole is also used as a treatment for dandruff (seborrheic dermatitis of the scalp) and for seborrheic dermatitis on other areas of the body, perhaps acting in these conditions by suppressing levels of the fungus Malassezia furfur on the skin.
Kevin Darnell Hart (born July 6, 1979) is an American comedian and actor. After winning several stand-up comedy competitions, Hart had his first breakthrough when Judd Apatow cast him in a recurring role on the TV series Undeclared (2001). Hart's comedic reputation continued to grow with the release of his first stand-up album I'm a Grown Little Man (2009). He has since released four more comedy albums: Seriously Funny (2010), Laugh at My Pain (2011), Let Me Explain (2013), and What Now? (2016). As an actor, Hart has had roles in films such as Paper Soldiers (2002), Scary Movie 3 (2003), Soul Plane (2004), In the Mix (2005), Little Fockers (2010), Think Like a Man (2012), Grudge Match (2013), Ride Along (2014), About Last Night (2014), Get Hard (2015), Central Intelligence (2016), The Secret Life of Pets film franchise (2016–2019), Ride Along 2 (2016), Captain Underpants: The First Epic Movie (2017), the Jumanji film franchise (2017–present), and Night School (2018). He also created and starred as a fictionalized version of himself in Real Husbands of Hollywood (2013–2016). In 2017, he launched the Laugh Out Loud Network, a subscription video streaming service in partnership with Lionsgate. Hart has received numerous accolades including the Mark Twain Prize for American Humor in 2024, and nominations for two Grammy Awards and four Primetime Emmy Awards. In 2015, Time magazine named him on its annual list of the 100 most influential people in the world.
PVC cables can use calcium carbonate at loadings of up to 70 phr (parts per hundred parts of resin) to improve mechanical properties (tensile strength and elongation) and electrical properties (volume resistivity). Polypropylene compounds are often filled with calcium carbonate to increase rigidity, a requirement that becomes important at high usage temperatures. Here the percentage is often 20–40%. It also routinely used as a filler in thermosetting resins (sheet and bulk molding compounds) and has also been mixed with ABS, and other ingredients, to form some types of compression molded "clay" poker chips. Precipitated calcium carbonate, made by dropping calcium oxide into water, is used by itself or with additives as a white paint, known as whitewashing. Calcium carbonate is added to a wide range of trade and do it yourself adhesives, sealants, and decorating fillers. Ceramic tile adhesives typically contain 70% to 80% limestone. Decorating crack fillers contain similar levels of marble or dolomite. It is also mixed with putty in setting stained glass windows, and as a resist to prevent glass from sticking to kiln shelves when firing glazes and paints at high temperature. In ceramic glaze applications, calcium carbonate is known as whiting, and is a common ingredient for many glazes in its white powdered form. When a glaze containing this material is fired in a kiln, the whiting acts as a flux material in the glaze.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.